An open label trial of OZ101 as an add-on therapy for the treatment of type 2 diabetes mellitus in patients on sulphonylurea therapy.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2017
At a glance
- Drugs OZ 101 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors OzStar Therapeutics
- 18 Dec 2017 Planned End Date changed from 28 Feb 2017 to 31 Aug 2018.
- 18 Dec 2017 Planned initiation date changed from 31 Oct 2016 to 2 Apr 2018.
- 06 Sep 2016 Status changed from recruiting to not yet recruiting.